Top

Published in:

Open Access 01-11-2012 | Review Article

A systematic review of the psychosocial difficulties relevant to patients with migraine

Authors: Alberto Raggi, Ambra Mara Giovannetti, Rui Quintas, Domenico D’Amico, Alarcos Cieza, Carla Sabariego, Jerome Edmound Bickenbach, Matilde Leonardi

Published in: The Journal of Headache and Pain | Issue 8/2012

Abstract

Migraine is a common disease which causes significant burden to individuals, in terms of personal suffering and activity reduction, and to societies, in terms of disease cost. The purpose of this study is to identify the most relevant psychosocial difficulties related to migraine, the variables associated with them and the most relevant determinants of their evolution over time. MEDLINE and PsychINFO were searched for studies published in English between 2000 and 2010 that examined psychosocial difficulties in persons with migraine with and without aura, from clinical trials and observational studies. Information on the description of each difficulty, its determinants of onset and change over time and associated variables were extracted and categorized at a higher level. In total, 34 difficulties have been collected from 51 papers: the most frequent were reduced vitality and fatigue, emotional problems, pain, difficulties at work, general physical and mental health, social functioning and global disability. Evidence exists that pharmacological treatments have an impact toward improvement in patients’ difficulties, in particular emotional problems, physical and mental health, difficulties with employment and global disability. Migraine treatments and decreased headaches frequency are the major determinants of improvements in psychosocial difficulties, while no information is available for determinants of worsening; understanding the role of such factors is of primary public health relevance, given the high prevalence and the relevant personal and societal costs of migraine.

Available only for authorised users

Headache Classification Subcommittee of the International Headache Society (2004) Classification of headache disorders, 2nd ed. Cephalalgia 24:9–160CrossRef

Stovner LJ, Andree C, Eurolight Steering Committee (2010) Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain 11:289–299PubMedCentralCrossRefPubMed

Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Andrée C (2012) The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 19:703–711CrossRefPubMed

Freitag F (2007) The cycle of migraine: patients’ quality of life during and between migraine attacks. Clin Ther 29:939–949CrossRefPubMed

Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF (2003) Migraine headache disability and health-related quality-of-life: a population-based case–control study from England. Cephalalgia 23:441–450CrossRefPubMed

Lj Stovner, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA (2007) The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27:193–210CrossRef

Bussone G, Usai S, Grazzi L, Rigamonti A, Solari A, D’Amico D (2004) Disability and quality of life in different primary headaches: results from Italian studies. Neurol Sci 25:S105–S107CrossRefPubMed

Leonardi M, Steiner TJ, Scher AT, Lipton RB (2005) The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF). J Headache Pain 6:429–440PubMedCentralCrossRefPubMed

Mula M, Viana M, Jauch R, Schmitz B, Bettucci D, Cavanna AE, Strigaro G, Tota MG, Israel H, Reuter U, Monaco F (2009) Health-related quality of life measures and psychiatric comorbidity in patients with migraine. Eur J Neurol 16:1017–1021CrossRefPubMed

10.

Lipton RB, Bigal ME, Stewart WF (2005) Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life. Neurology 65:S50–S58CrossRefPubMed

11.

Leonardi M, Raggi A, Bussone G, D’Amico D (2010) Health-related quality of life, disability and severity of disease patients with migraine attending to a specialty headache center. Headache 50:1576–1586CrossRefPubMed

12.

Lipton RB, Bigal ME, Kolodner K, Stewart WF, Liberman JN, Steiner TJ (2003) The family impact of migraine: population-based studies in the USA and UK. Cephalagia 23:429–440CrossRef

13.

Smitherman TA, Ward TN (2011) Psychosocial factors of relevance to sex and gender studies in headache. Headache 51:923–931CrossRefPubMed

14.

World Health Organization (2001) The International Classification of Functioning, Disability and Health-ICF. WHO, Geneva

15.

Headache Classification Committee of the International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8:1–98CrossRef

16.

National Institute for Mental Health and Clinical Excellence (2009) The guideline manual. NICE, London

17.

Cieza A, Geyh S, Chatterji S, Kostanjsek N, Ustün B, Stucki G (2005) ICF linking rules: an update based on lessons learned. J Rehabil Med 37:212–218CrossRefPubMed

18.

Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, Britten N, Roen K, Duffy S (2006) Guidance on the conduct of Narrative synthesis in systematic Reviews. A Product from the ESCR Methods Programme ESRC Methods Program, Lancaster

19.

Cabello M, Mellor-Marsá B, Sabariego C, Cieza A, Bickenbach J, Ayuso-Mateos JL (2012) Psychosocial features of depression: a systematic literature review. J Affect Disord 141:22–33

20.

Farmer K, Cady R, Bleiberg J, Reeves D, Putnam G, O’Quinn S, Batenhorst A (2001) Sumatriptan nasal spray and cognitive function during migraine: results of an open-label study. Headache 41:377–384CrossRefPubMed

21.

Dasbach EJ, Carides GW, Gerth WC, Santanello NC, Pigeon JG, Kramer (2000) Work and productivity loss in the rizatriptan multiple attack study. Cephalalgia 20:830–834CrossRefPubMed

22.

Mulder EJ, Passchier J, Linssen WH, de Geus EJ (2001) Effects of medication use on health state in postictal migraineurs. Headache 41:782–791CrossRefPubMed

23.

Brandes JL, Kudrow DB, Rothrock JF, Rupnow MF, Fairclough DL, Greenberg SJ (2006) Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clin Proc 81:1311–1319CrossRefPubMed

24.

Garcia-Monco JC, Foncea N, Bilbao A, Ruiz de Velasco I, Gomez-Beldarrain M (2007) Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients. Cephalalgia 27:920–928CrossRefPubMed

25.

Fuh JL, Wang SJ (2006) Comparison of Short Form-36 and Migraine Disability Assessment questionnaire in patients with migraine. Clin J Pain 22:564–568CrossRefPubMed

26.

Freitag F, Smith T, Mathew N, Rupnow M, Greenberg S, Mao L, Finlayson G, Wright P, Biondi D, AEGIS Investigator Study Group (2008) Effect of early intervention with almotriptan vs. placebo on migraine-associated functional disability: results from the AEGIS Trial. Headache 48:341–354CrossRefPubMed

27.

Santanello NC, Davies G, Allen C, Kramer M, Lipton R (2002) Determinants of migraine-specific quality of life. Cephalalgia 22:680–685CrossRefPubMed

28.

Burk CT, Gilderman A, Salas J, Berenbeim D, Nichol MB (2003) The impact of an over-the counter migraine medication program on quality of life. Headache 43:191–201CrossRefPubMed

29.

Bordini CA, Mariano da Silva H, Garbelini RP, Teixeira SO, Speciali JG (2005) Effect of preventive treatment on health-related quality of life in episodic migraine. J Headache Pain 6:387–391PubMedCentralCrossRefPubMed

30.

D’Amico D, Solari A, Usai S, Santoro P, Bernardoni P, Frediani F, De Marco R, Massetto N, Bussone G, Progetto Cefalee Lombardia Group (2006) Improvement in quality of life and activity limitations in migraine patients after prophylaxis. A prospective longitudinal multicentre study. Cephalalgia 26:691–696CrossRefPubMed

31.

Lainez MJ, Lopez A, Pascual AM (2005) Effects on productivity and quality of life of rizatriptan for acute migraine: a workplace study. Headache 45:883–890CrossRefPubMed

32.

Dahlöf C, Loder E, Diamond M, Rupnow M, Papadopoulos G, Mao L (2007) The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials. Health Qual Life Outcomes 5:56PubMedCentralCrossRefPubMed

33.

Cady R, Schreiber C (2008) Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache 48:900–913CrossRefPubMed

34.

Gori S, Morelli N, Maestri M, Fabbrini M, Bonanni E, Murri L (2005) Sleep quality, chronotypes and preferential timing of attacks in migraine without aura. J Headache Pain 6:258–260PubMedCentralCrossRefPubMed

35.

Lucas C, Geraud G, Valade D, Chautard MH, Lantéri-Minet M (2006) Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache 46:715–725CrossRefPubMed

36.

Calandre EP, Bembibre J, Arnedo ML, Becerra D (2002) Cognitive disturbances and regional cerebral blood flow abnormalities in migraine patients: their relationship with the clinical manifestations of the illness. Cephalalgia 22:291–302CrossRefPubMed

37.

Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF (2000) Migraine, quality of life, and depression: a population-based case–control study. Neurology 55:629–635CrossRefPubMed

38.

Vasudeva S, Claggett AL, Tietjen GE, McGrady AV (2003) Biofeedback-assisted relaxation in migraine headache: relationship to cerebral blood flow velocity in the middle cerebral artery. Headache 43:245–250CrossRefPubMed

39.

Pradalier A, Lanteri-Minet M, Geraud G, Allain H, Lucas C, Delgado A (2004) The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care. CNS Drugs 18:1149–1463CrossRefPubMed

40.

Vos J, Passchier J (2003) Reduced impact of migraine in everyday life: an observational study in the Dutch Society of Headache Patients. Headache 43:645–650CrossRefPubMed

41.

Nicholson R, Nash J, Andrasik F (2005) A self-administered behavioral intervention using tailored messages for migraine. Headache 45:1124–1239CrossRefPubMed

42.

Smith T, Blumenthal H, Diamond M, Mauskop A, Ames M, McDonald S, Lener S, Burch S (2007) Sumatriptan/Naproxen sodium for migraine: efficacy, health related quality of life, and satisfaction outcomes. Headache 47:683–692CrossRefPubMed

43.

Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, Biondi D, Greenberg SJ, Hulihan J, CAPSS-277 Investigator Group (2009) Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 31:542–559CrossRefPubMed

44.

Lawler SP, Cameron LD (2006) A randomized, controlled trial of massage therapy as a treatment for migraine. Ann Behav Med 32:50–59CrossRefPubMed

45.

John PJ, Sharma N, Sharma CM, Kankane A (2007) Effectiveness of yoga therapy in the treatment of migraine without aura: a randomized controlled trial. Headache 47:654–661CrossRefPubMed

46.

Sculpher M, Millson D, Meddis D, Poole L (2002) Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: the Disability in Strategies for Care (DISC) study. Pharmacoeconomics 20:91–100CrossRefPubMed

47.

Lofland JH, Kim SS, Batenhorst AS, Johnson NE, Chatterton ML, Cady RK, Kaniecki R, Nash DB (2001) Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clin Proc 76:1093–1101CrossRefPubMed

48.

Silberstein SD, Cady RK, Sheftell FD, Almas M, Parsons B, Albert KS (2007) Efficacy of eletriptan in migraine-related functional impairment: functional and work productivity outcomes. Headache 47:673–682CrossRefPubMed

49.

Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B, Ertas M, Lanteri-Minet M, Reuter U, Sánchez Del Río M, Schoenen J, Schwalen S, van Oene J, TOPMAT-MIG-303 Investigators Group (2007) Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 6:1054–1062CrossRefPubMed

50.

Schellenberg R, Lichtenthal A, Wohling H, Graf C, Brixius K (2008) Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment? Headache 48:118–125PubMed

51.

Guyuron B, Kriegler JS, Davis J, Amini SB (2005) Comprehensive surgical treatment of migraine headaches. Plast Reconstr Surg 115:1–9PubMed

52.

Guyuron B, Reed D, Kriegler JS, Davis J, Pashmini N, Amini S (2009) A placebo-controlled surgical trial of the treatment of migraine headaches. Plast Reconstr Surg 124:461–468CrossRefPubMed

53.

Lee ST, Park JH, Kim M (2005) Efficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study. Headache 45:1004–1011CrossRefPubMed

54.

Dowson A, Bundy M, Salt R, Kilminster S (2007) Patient preference for triptan formulations: a prospective study with zolmitriptan. Headache 47:1144–1151CrossRefPubMed

55.

Diamond M, Dahlof C, Papadopoulos G, Neto W, Wu SC (2005) Topiramate improves health-related quality of life when used to prevent migraine. Headache 45:1023–1230CrossRefPubMed

56.

Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, Gutiérrez I, Rivera-Castaño L, Trujillo-Hernández B, Baltazar LM (2008) Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study. Eur Neurol 59:237–242CrossRefPubMed

57.

Narin SO, Pinar L, Erbas D, Oztürk V, Idiman F (2003) The effects of exercise and exercise-related changes in blood nitric oxide level on migraine headache. Clin Rehabil 17:624–630CrossRefPubMed

58.

Rigatelli G, Cardaioli P, Giordan M, Dell’Avvocata F, Braggion G, Chianaglia M, Roncon L (2009) Transcatheter interatrial shunt closure as a cure for migraine: can it be justified by paradoxical embolism-risk-driven criteria? Am J Med Sci 337:179–181CrossRefPubMed

59.

Merelle SY, Sorbi MJ, van Doornen LJ, Passchier J (2008) Lay trainers with migraine for a home-based behavioral training: a 6-month follow-up study. Headache 48:1311–1325CrossRefPubMed

60.

Lemstra M, Stewart B, Olszynski WP (2002) Effectiveness of multidisciplinary intervention in the treatment of migraine: a randomized clinical trial. Headache 42:845–854CrossRefPubMed

61.

Stronks DL, Tulen JH, Bussmann HB, Mulder LJ, Passchier J (2003) Effects of naratriptan versus naproxen on daily functioning in the acute treatment of migraine: a randomized, double-blind, double-dummy, crossover study. Headache 43:845–852CrossRefPubMed

62.

Wacogne C, Lacoste JP, Guillibert E, Hugues FC, Le Jeunne C (2003) Stress, anxiety, depression and migraine. Cephalalgia 23:451–455CrossRefPubMed

63.

Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G (2003) Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289:65–69CrossRefPubMed

64.

Frediani F, Martelletti P, Bussone G (2004) Measure of negative impact of migraine on daily activities, social relationships and therapeutic approach. Neurol Sci 25:S249–S250CrossRefPubMed

65.

Holroyd KA, Drew JB, Cottrell CK, Romanek KM, Heh V (2007) Impaired functioning and quality of life in severe migraine: the role of catastrophizing and associated symptoms. Cephalalgia 27:1156–1165PubMedCentralCrossRefPubMed

66.

Barbanti P, Fabbrini G, Aurilia C, Vanacore N, Cruccu G (2007) A case–control study on excessive daytime sleepiness in episodic migraine. Cephalalgia 27:1115–1119CrossRefPubMed

67.

Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, Rivera-Castaño L, Garcia-Solorzano A, López-Blanca C, Membrila-Maldonado M, Muñoz-Solis R (2007) Subcutaneous histamine versus sodium valproate in migraine prophylaxis: a randomized, controlled, double-blind study. Eur J Neurol 14:1079–1084CrossRefPubMed

68.

Park JW, Shin HE, Kim JS, Lee KS (2008) Assessing migraine disability by diary-based measurement: relationship to the characteristics of individual headache attacks. Eur J Neurol 15:817–821CrossRefPubMed

69.

Geraud G, Valade D, Lanteri-Minet M, Radat F, Lucas C, Vives E, Joubert JM, Mekies C (2008) SMILE: first observational prospective cohort study of migraine in primary care in France. Description of methods and study population. Cephalalgia 28:164–173PubMed

70.

Varkey E, Cider A, Carlsson J, Linde M (2009) A study to evaluate the feasibility of an aerobic exercise program in patients with migraine. Headache 49:563–570CrossRefPubMed

71.

Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, Sawyer J (1999) An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 53:988–994CrossRefPubMed

72.

Franzini A, Messina G, Cordella R, Marras C, Broggi G (2010) Deep brain stimulation of the posteromedial hypothalamus: indications, long-term results, and neurophysiological considerations. Neurosurg Focus 29:E13CrossRefPubMed

73.

Proietti Cecchini A, Leone M, Manzoni GC, Torelli P, Bussone G (2012) Drug-resistant chronic migraine: the Italian GON project. Neurol Sci 33:S33–S36CrossRefPubMed

74.

Cecchini AP, Mea E, Tullo V, Curone M, Franzini A, Broggi G, Savino M, Bussone G, Leone M (2009) Vagus nerve stimulation in drug-resistant daily chronic migraine with depression: preliminary data. Neurol Sci 30:S101–S104CrossRefPubMed

75.

Berger A, Bloudek LM, Varon SF, Oster G (2012). Adherence with Migraine Prophylaxis in Clinical Practice. Pain Pract 12:541–549

76.

Katić BJ, Krause SJ, Tepper SJ, Hu HX, Bigal ME (2010) Adherence to acute migraine medication: what does it mean, why does it matter? Headache 50:117–129CrossRefPubMed

77.

D’Amico D, Tepper SJ (2008) Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatr Dis Treat 4:1155–1167PubMedCentralCrossRefPubMed

78.

Moschiano F, D’Amico D, Canavero I, Pan I, Micieli G, Bussone G (2011) Migraine and depression: common pathogenetic and therapeutic ground? Neurol Sci 32:S85–S88CrossRefPubMed

79.

Antonaci F, Nappi G, Galli F, Manzoni GC, Calabresi P, Costa A (2011) Migraine and psychiatric comorbidity: a review of clinical findings. J Headache Pain 12:115–125PubMedCentralCrossRefPubMed

80.

Pompili M, Serafini G, Del Casale A, Rigucci S, Innamorati M, Girardi P, Tatarelli R, Lester D (2009) Improving adherence in mood disorders: the struggle against relapse, recurrence and suicide risk. Expert Rev Neurother 9:985–1004CrossRefPubMed

81.

Le H, Tfelt-Hansen P, Skytthe A, Kyvik KO, Olesen J (2011) Association between migraine, lifestyle and socioeconomic factors: a population-based cross-sectional study. J Headache Pain 12:157–172PubMedCentralCrossRefPubMed

82.

Winter AC, Hoffmann W, Meisinger C, Evers S, Vennemann M, Pfaffenrath V, Fendrich K, Baumeister SE, Kurth T, Berger K (2011) Association between lifestyle factors and headache. J Headache Pain 12:147–155PubMedCentralCrossRefPubMed

83.

Gaul C, van Doorn C, Webering N, Dlugaj M, Katsarava Z, Diener HC, Fritsche G (2011) Clinical outcome of a headache-specific multidisciplinary treatment program and adherence to treatment recommendations in a tertiary headache center: an observational study. J Headache Pain 12:475–483PubMedCentralCrossRefPubMed

84.

Ware JE (2000) SF-36 health survey update. Spine 25:3130–3139CrossRefPubMed

Title: A systematic review of the psychosocial difficulties relevant to patients with migraine
Authors: Alberto Raggi
Ambra Mara Giovannetti
Rui Quintas
Domenico D’Amico
Alarcos Cieza
Carla Sabariego
Jerome Edmound Bickenbach
Matilde Leonardi
Publication date: 01-11-2012
Publisher: Springer Milan
Published in: The Journal of Headache and Pain / Issue 8/2012
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1007/s10194-012-0482-1

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

A systematic review of the psychosocial difficulties relevant to patients with migraine

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2012

Brainstem 1H-MR spectroscopy in episodic and chronic migraine

Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial

“Burning mouth syndrome in Parkinson’s disease: dopamine as cure or cause?” Letter to the Editor Reply

Drug-induced burning mouth syndrome: a new clinico-pathological entity?

Drug-dependence behaviour and outcome of medication-overuse headache after treatment

Cesar Fernandez-de-las-Penas, Leon Chaitow, and Jean Schoenen (eds.): Multidisciplinary management of migraine